Mitchison 1989.
Methods | Randomised clinical trial. | |
Participants | Country: UK. Number randomised: 36. Post‐randomisation dropouts: 0 (0%). Revised sample size: 36. Mean age: 55 years. Females: 33 (91.7%). Symptomatic participants: 35 (97.2%). AMA positive: not stated. Responders: not stated. Mean follow‐up period (for all groups): all participants followed up for 36 months. Inclusion criteria
Exclusion criteria
|
|
Interventions | Participants were randomly assigned to 2 groups. Group 1: glucocorticosteroids (n = 19). Further details: prednisolone: 10 mg/day for 36 months (loading dose was used). Group 2: placebo (n = 17). |
|
Outcomes | Mortality. | |
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Quote: "Patients were paired according to the presence or absence of cirrhosis, their age by decade, menopausal status (for women) and their serum bilirubin (greater or less than 30 µmoles per litre)". Comment: minimisation used. |
Allocation concealment (selection bias) | Low risk | Quote: "Patients were paired according to the presence or absence of cirrhosis, their age by decade, menopausal status (for women) and their serum bilirubin (greater or less than 30 µmoles per litre)". Comment: minimisation used. |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Quote: "Study was double‐blind for the first year, single blind thereafter (patients were blinded)". |
Blinding of outcome assessment (detection bias) All outcomes | High risk | Quote: "Study was double‐blind for the first year, single blind thereafter (patients were blinded)". |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Comment: no post‐randomisation dropouts. |
Selective reporting (reporting bias) | High risk | Comment: adverse events not reported. |
For‐profit bias | Unclear risk | Comment: information not available. |
Other bias | Low risk | Comment: no other bias. |